Pfizer will discontinue development of drugs for heart disease, obesity and bone health as part of its plan to focus research on Alzheimer’s disease, diabetes, inflammation/immunology, oncology, pain and psychoses (schizophrenia), according to a company memo. The shift in R&D focus was led by president Martin Mackay, a Pfizer research executive who took over the division in October of last year.     “It’s a continuous process to constantly evaluate our pipeline and make ...